The developmental and epileptic encephalopathies encompass a group of rare syndromes
characterised by severe drug-resistant epilepsy with onset in childhood and significant …

We performed a systematic literature review and narrative synthesis according to a pre‐
registered protocol (Prospero: CRD42022376561) to identify the evidence associated with …

Epilepsy is common in early childhood. In this age group it is associated with high rates of
therapy-resistance, and with cognitive, motor, and behavioural comorbidity. A large number …

A monogenic etiology can be identified in up to 40% of people with severe epilepsy. To
address earlier and more appropriate treatment strategies, clinicians are required to know …

Over time, with careful delineation of Dravet syndrome, we have gained experience in
treatments most likely to lead to improvement in seizures, as well as those that should be …

Dravet syndrome (DS) is a form of genetic refractory epilepsy. More than 80% of DS patients
carry pathogenic SCN1A mutations, and this percentage is actually higher due to false …

Dravet syndrome is a rare but severe epilepsy syndrome that begins in the first year of life
with recurrent seizures triggered by fever that are typically prolonged and hemiclonic. The …

Dravet Syndrome (DS) is a rare and severe infantile-onset epileptic encephalopathy. DS
research focuses mainly on children. We did a systematic review, completed on January 18 …

Objective Fenfluramine has been shown to provide clinically meaningful and statistically
significant reductions in convulsive seizure frequency in children and adolescents (aged 2 …

Objectives Stiripentol, fenfluramine, and cannabidiol are licensed add‐on therapies to treat
seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing …